Aadi Bioscience, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AADI research report →
About the company
Aadi Bioscience, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing highly targeted therapies for cancers defined by specific genetic alterations within the mTOR pathway. Its flagship drug candidate, FYARRO, is an investigational therapeutic composed of sirolimus conjugated with albumin.
- CEO
- David J. Lennon
- IPO
- 2018
- Employees
- 53
- HQ
- Pacific Palisades, CA, US
Price Chart
- Market Cap
- $94.89M
- P/E
- -2.49
- P/S
- 0.00
- P/B
- 2.50
- EV/EBITDA
- -1.49
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -79.63%
- ROIC
- -105.62%
- Revenue
- $7.14M · -72.50%
- Net Income
- $-20,596,000 · 67.66%
- EPS
- $-0.03 · 98.59%
- Op Income
- $-114,400,000
- FCF YoY
- -60.10%
- 52W High
- $3.81
- 52W Low
- $1.21
- 50D MA
- $2.56
- 200D MA
- $2.16
- Beta
- 0.34
- Avg Volume
- 200.71K
Get TickerSpark's AI analysis on AADI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 4, 25 | Dalal Anupam | other | 1,561,000 |
| Mar 4, 25 | Castelein Caley | other | 1,666,000 |
| Mar 4, 25 | Zhao Baiteng | other | 1,250,000 |
| Mar 4, 25 | Dornan David | other | 687,979 |
| Mar 4, 25 | BALL BRYAN | other | 100,000 |
| Mar 1, 25 | BALL BRYAN | other | 5,000 |
| Mar 3, 25 | BALL BRYAN | sell | 2,147 |
| Mar 1, 25 | BALL BRYAN | other | 5,000 |
| Feb 28, 25 | Aghazadeh Behzad | other | 8,333,000 |
| Mar 1, 25 | Giacobello Scott M. | other | 6,750 |
Our AADI coverage
Recent articles, reports, and earnings notes.
No research on AADI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AADI report →Similar companies
Peers in the same neighborhood.